PMID- 35467088
OWN - NLM
STAT- MEDLINE
DCOM- 20220829
LR  - 20220901
IS  - 1899-5276 (Print)
IS  - 1899-5276 (Linking)
VI  - 31
IP  - 8
DP  - 2022 Aug
TI  - Impact of moderately reduced renal function on the diagnostic and prognostic 
      value of galectin-3 in patients with exertional dyspnea.
PG  - 873-879
LID - 10.17219/acem/147665 [doi]
AB  - BACKGROUND: Blood concentration of galectin-3 (Gal-3) - a biomarker of fibrosis 
      useful in diagnostics and prognostication in heart failure (HF) - is known to be 
      elevated in patients with renal impairment, a condition which often accompanies 
      cardiac insufficiency. OBJECTIVES: To investigate the effect of moderately 
      reduced renal function (estimated glomerular filtration rate (eGFR) 30-60 
      mL/min/1.73 m2) on the diagnostic and prognostic utility of circulating Gal-3 in 
      patients with HF with preserved ejection fraction (HFpEF). MATERIAL AND METHODS: 
      Clinical, biochemical and echocardiographic variables were collected at baseline 
      in 154 patients with HFpEF: 101 with normal and 53 with moderately reduced renal 
      function, who were followed up for 48 (24-60) months for HF hospitalization and 
      cardiovascular (CV) death (composite endpoint). RESULTS: Patients with moderately 
      impaired renal function were characterized by higher age, Meta-Analysis Global 
      Group in Chronic Heart Failure (MAGGIC) risk score, Gal-3, B-type natriuretic 
      peptide (BNP) and New York Heart Association (NYHA) class, lower hemoglobin, and 
      more advanced left ventricular diastolic dysfunction. Older age, female sex and 
      deeper impairment of renal performance were determinants of higher Gal-3 blood 
      concentrations. Lower exercise capacity (lower peak VO2) was associated with 
      higher Gal-3 level and more pronounced renal impairment. Multivariable regression 
      analysis demonstrated the significance of renal dysfunction as a determinant of 
      lower exercise capacity and revealed a significant interaction between Gal-3 and 
      eGFR with respect to peak VO2. The addition of Gal-3 to the prognostic models 
      based on clinical data improved their predictive power for the study endpoint. 
      The Kaplan-Meier analysis revealed that the presence of moderately reduced renal 
      function with eGFR 30-60 mL/min/1.73 m2 did not enhance the increased risk of 
      adverse outcome associated with Gal-3 above the median. CONCLUSIONS: In patients 
      with HFpEF, the coexistence of moderate renal dysfunction does not deteriorate 
      the prognostic usefulness of circulating Gal-3. However, renal impairment 
      modifies the association between Gal-3 and exercise capacity, which supports the 
      need to adjust for kidney function when interpreting the contribution of Gal-3 to 
      exercise intolerance in this population.
FAU - Karolko, Bozena
AU  - Karolko B
AD  - Institute of Heart Diseases, Wroclaw Medical University, Poland.
FAU - Serafin, Adam
AU  - Serafin A
AD  - Institute of Heart Diseases, Wroclaw Medical University, Poland.
FAU - Przewlocka-Kosmala, Monika
AU  - Przewlocka-Kosmala M
AD  - Institute of Heart Diseases, Wroclaw Medical University, Poland.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - Poland
TA  - Adv Clin Exp Med
JT  - Advances in clinical and experimental medicine : official organ Wroclaw Medical 
      University
JID - 101138582
RN  - 0 (Galectin 3)
SB  - IM
MH  - Dyspnea
MH  - Female
MH  - Galectin 3
MH  - *Heart Failure/diagnosis
MH  - Humans
MH  - Kidney/physiology
MH  - *Kidney Diseases
MH  - Prognosis
MH  - Stroke Volume
MH  - Ventricular Function, Left
OTO - NOTNLM
OT  - galectin-3
OT  - heart failure with preserved ejection fraction
OT  - prognosis
OT  - renal dysfunction
EDAT- 2022/04/26 06:00
MHDA- 2022/08/30 06:00
CRDT- 2022/04/25 08:59
PHST- 2022/04/26 06:00 [pubmed]
PHST- 2022/08/30 06:00 [medline]
PHST- 2022/04/25 08:59 [entrez]
AID - 10.17219/acem/147665 [doi]
PST - ppublish
SO  - Adv Clin Exp Med. 2022 Aug;31(8):873-879. doi: 10.17219/acem/147665.